We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
NBTX

Price
3.33
Stock movement up
+0.15 (4.86%)
Company name
Nanobiotix
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
157.95M
Ent value
200.07M
Price/Sales
6.13
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-7.00%
1 year return
-47.94%
3 year return
-21.66%
5 year return
-
10 year return
-
Last updated: 2025-04-12

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

NBTX does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales6.13
Price to Book-
EV to Sales7.77

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count47.40M
EPS (TTM)-0.59
FCF per share (TTM)-0.06

Income statement

Loading...
Income statement data
Revenue (TTM)25.75M
Gross profit (TTM)25.75M
Operating income (TTM)-23.08M
Net income (TTM)-27.67M
EPS (TTM)-0.59
EPS (1y forward)-0.78

Margins

Loading...
Margins data
Gross margin (TTM)100.00%
Operating margin (TTM)-89.65%
Profit margin (TTM)-107.48%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash66.33M
Net receivables3.12M
Total current assets80.46M
Goodwill0.00
Intangible assets9.00K
Property, plant and equipment0.00
Total assets86.68M
Accounts payable4.77M
Short/Current long term debt49.17M
Total current liabilities56.52M
Total liabilities108.46M
Shareholder's equity-21.78M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-3.44M
Capital expenditures (TTM)491.50K
Free cash flow (TTM)-2.66M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-31.92%
Return on Invested Capital164.94%
Cash Return on Invested Capital15.83%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open3.25
Daily high3.33
Daily low3.21
Daily Volume1K
All-time high19.68
1y analyst estimate10.40
Beta1.40
EPS (TTM)-0.59
Dividend per share-
Ex-div date-
Next earnings date20 May 2025

Downside potential

Loading...
Downside potential data
NBTXS&P500
Current price drop from All-time high-83.07%-12.89%
Highest price drop-100.00%-56.47%
Date of highest drop8 Mar 20239 Mar 2009
Avg drop from high-61.97%-11.07%
Avg time to new high272 days12 days
Max time to new high1063 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
NBTX (Nanobiotix) company logo
Marketcap
157.95M
Marketcap category
Small-cap
Description
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
Employees
110
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...